Medpace Holdings, Inc.
No enriched coverage for $MEDP in the last 7 days.
Troendle August J. (President & CEO) sold 11,824 shares of Medpace Holdings, Inc. (MEDP) at an average of $601.49 ($600.39–$601.53, $7.11M total) across 2 trades over 2026-08-12 to 2026-08-13.
McCarthy Cornelius P. III sold 1,140 shares of Medpace Holdings, Inc. (MEDP) at $605.37 ($0.69M total) on 2026-08-11.
Troendle August J. (President & CEO) sold 23,144 shares of Medpace Holdings, Inc. (MEDP) at an average of $604.25 ($601.53–$605.11, $13.98M total) across 2 trades over 2026-08-10 to 2026-08-11.
Recent MEDP coverage spans insider activity, financial news and earnings.
In the last 30 days, MEDP insiders filed 9 SEC Form 4 transactions — no purchases and 9 sales ($31.1M). The most active reporter was Troendle August J., President & CEO, with 6 filings.
Insider selling is a near-term sentiment datapoint, but it is not a fundamental catalyst by itself.
This is a routine insider sale with no 10b5-1 plan disclosed, but it does not provide new fundamentals or guidance.
The filing discloses a large insider sale by the CEO, which can modestly pressure sentiment but is not, by itself, a fundamental change.
This is an insider sale disclosure, not a company fundamental update. It may slightly affect sentiment but is unlikely to change near-term valuation on its own.
The article provides a fresh insider-sale datapoint that can shift near-term sentiment, though it is not a fundamental change by itself.
alphai scores every news story that mentions MEDP with an AI model for sentiment and relevance, and aggregates insider trades from Medpace Holdings, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Troendle August J. (President & CEO) sold 11,824 shares of Medpace Holdings, Inc. (MEDP) at an average of $601.49 ($600.39–$601.53, $7.11M total) across 2 trades over 2026-08-12 to 2026-08-13.
1 min readMcCarthy Cornelius P. III sold 1,140 shares of Medpace Holdings, Inc. (MEDP) at $605.37 ($0.69M total) on 2026-08-11.
1 min readTroendle August J. (President & CEO) sold 23,144 shares of Medpace Holdings, Inc. (MEDP) at an average of $604.25 ($601.53–$605.11, $13.98M total) across 2 trades over 2026-08-10 to 2026-08-11.
2 min readMcCarthy Cornelius P. III sold 795 shares of Medpace Holdings, Inc. (MEDP) at $585.07 ($0.47M total) on 2026-08-07.
1 min readMedpace Holdings CEO and President J. Troendle sold 7,238 shares of MEDP for about $4.35M, according to a July 29 Form 4 filing with the SEC. The article also cites MEDP revenue growth of 17.24% over the three months ended June 30, 2026, and a debt-to-equity ratio of 0.28. MEDP shares were about $574.55, down 2.51% Thursday morning.
3 min readTroendle August J. (President & CEO) sold 7,238 shares of Medpace Holdings, Inc. (MEDP) at an average of $600.44 ($600.01–$600.85, $4.35M total) across 2 trades over 2026-07-27 to 2026-07-28.
1 min readBURWIG SUSAN E (Exec. VP, Operations) sold 7,500 shares of Medpace Holdings, Inc. (MEDP) at $600.00 ($4.50M total) on 2026-07-28.
1 min readSimply Wall St says Medpace Holdings (MEDP) trades near about $601 after a 5-year 242% return. Using a DCF based on ~$706.3M free cash flow, intrinsic value is estimated at ~$654 per share, about 8% higher. The article also cites a P/E of ~34.2x versus a tailored fair P/E of ~20.7x, implying earnings-multiple overvaluation.
6 min readMedpace Holdings reported Q2 2026 revenue of $707.3 million, up 17.2% year over year, citing growth from small biopharma clients and expansion in Metabolic and Oncology. The company said its net book-to-bill improved to 1.13x and that backlog metrics supported raising its 2026 revenue forecast, according to the report.
1 min readZacks Investment Research reports Medpace Holdings (MEDP) hit a 52-week high of $677.9 and is up 16.5% over the past month. The firm says Medpace beat EPS and revenue consensus in each of the last four quarters, including July 22, 2026 results (EPS $4.25 vs $4.08; revenue 1.12% above). FY EPS is expected at $17.12 on $2.81 revenue.
6 min read
